Sevaro Health, a US-based neurological care company, has completed an oversubscribed $39m Series B funding round to expand its AI-powered speciality care platform.

The Synapse AI platform is designed to link hospital teams and virtual specialists across the complete patient journey. It functions as a workforce extension, preventing gaps in coverage and reducing burnout.

Through this platform, Sevaro collaborates with hospitals in the country to enhance neuroscience services access, improve patient outcomes, and promote financial sustainability in the long term.

The company also intends to use the proceeds to accelerate innovation and strengthen integrations with health system partners.

Investment platform Valtruis led the funding round alongside Intermountain Ventures, with early investors Catalyst and APA providing continued support.

The funding targets hospitals grappling with staff shortages, increasing patient demand.

Valtruis managing partner Anna Haghgooie said: "Sevaro has built something unique - a scalable model for virtual neuroscience backed by proven results. They're giving hospitals the resources needed to deliver advanced care to communities, without compromise." 

Sevaro provides care across the entire continuum, from ambulance services to ambulatory care, including coordinated care solutions, physical medicine, lifestyle coaching, and virtual neurology clinics.

Its care model has now been extended to other specialities, including neurosurgery, cardiology, infectious diseases, surgery, hospital medicine, neurointerventional radiology and behavioural health.

Sevaro Health founder and CEO Dr Rajiv Narula said: "This funding validates what we've believed from day one, that hospitals deserve a model where quality and financial performance go hand in hand.

"Synapse AI isn't just a solution for coverage, it's our commitment to building the future of speciality care where physicians are proud to practise, and every patient in the world receives the care they deserve."